Breakthrough results for INOVIQ’s ovarian cancer test
[videojs_hls url=’//du7x25at22z7c.cloudfront.net/501985/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/2024/Int_IIQ_360_241211.jpg’]
INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
The company's breast cancer screen test has also demonstrated superior accuracy over current tests.
Copyright 2024 – Finance News Network
Source: Finance News Network